ALB and head and neck squamous cell carcinoma: In this cohort of patients with R/M HNSCC treated with nivolumab, pretreatment serum albumin levels ≥3.5 g/dL were identified as an independent predictor of long-term OS (OS ≥ 2 years), along with an ECOG performance status score of 0 or 1.